We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Pioneering Microscopy Technique Improves Diagnosis of Glioblastoma Brain Tumors

By LabMedica International staff writers
Posted on 16 Oct 2024

Along the brain’s largest nerve fiber highway, known as the corpus callosum, travel cells that form one of the most lethal brain cancers, glioblastomas. More...

Now, scientists have developed a cellular detector by integrating artificial intelligence (AI) with a cutting-edge microscope, enabling them to visualize and monitor specific cells with unprecedented clarity in deep brain tissue, including along this superhighway. The researchers believe that understanding the early ‘traffic patterns’ of cancer cells along the corpus callosum could aid in establishing a biomarker for the earlier detection of glioblastomas in patients, potentially enhancing future diagnostic tools.

This collaborative endeavor between EMBL (Heidelberg, Germany) and Heidelberg University (Heidelberg, Germany) builds upon a new microscopy technique developed by EMBL researchers in 2021 in association with colleagues from Germany, Austria, Argentina, China, France, the United States, India, and Jordan. The EMBL team worked with these diverse partners to tackle some of the challenges neuroscientists encounter when studying deep brain regions. Previously, the diffuse nature of brain tissue made it challenging for scientists to observe neurons and glial cells, such as astrocytes, and to investigate their communication within the cortex. This difficulty extended to visualizing neural cells in the hippocampus, another deep brain area critical for spatial memory and navigation. The researchers' new method utilized advanced microscopy techniques that offered a broader and clearer view while compensating for the distortion caused by scattered light waves in deep brain tissue.

Now, in a study published in the journal Nature Communications, the EMBL researchers collaborated with neuroscientists, neurooncologists, and AI specialists to enhance this microscope further. The outcome is a device capable of observing living neurons and other brain cell types deep within the brain over extended periods. Glioblastomas are predominantly a white-matter disease. The new advanced imaging technique allowed the team to study these tumor cells within their microenvironment in the white matter. This capability was vital for understanding how tumor cells invade the densely myelinated (insulated) fiber “lanes” of the corpus callosum and subsequently adapt and spread throughout the brain. This invasion is also linked to the critical structures of the brain that glioblastomas invade in a lethal manner.

A key aspect of this recent collaboration was the integration of AI, which helped to reduce noise in the images, resulting in much clearer contrast. The AI can differentiate various structures within the white matter, such as myelinated fibers and blood vessels, which is significant for multiple reasons. A tailored workflow enabled the researchers to separate blood vessel signals from those of the myelinated neural fibers, clarifying the microenvironment of the tumor cells. As a result, the researchers identified a potential microscopic imaging biomarker associated with the structural characteristics of the white matter microenvironment. This innovative workflow paves the way for identifying imaging patterns for glioblastomas, allowing for earlier detection than currently possible. Their next steps involve integrating additional advanced imaging modalities to create practical tools for standard clinical applications.

“These findings also help explain the current challenges in detecting glioblastoma cells at the tumor’s infiltrative edges using conventional MRI techniques, which are the standard in clinical imaging,” said Varun Venkataramani at the Neurology Clinic of the University Hospital Heidelberg. “As a neuroscientist, neurologist, and neurooncologist, I see potential for this technology to bridge the gap between laboratory research and clinical application, improving how we could diagnose and potentially treat brain tumors.”

 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Gastrointestinal Panel
Xpert® GI Panel
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.